ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ASXSF Elysee Development Corp (PK)

0.23824
0.04154 (21.12%)
23 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Elysee Development Corp (PK) USOTC:ASXSF OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.04154 21.12% 0.23824 0.193 0.3345 0.23824 0.23824 0.23824 1,106 21:00:35

- Current report filing (8-K)

17/07/2012 10:04pm

Edgar (US Regulatory)


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  July 17,  2012

 

 

REMEDENT, INC.

(Exact name of Registrant as Specified in its Charter)

 

 

Nevada

(State or Other Jurisdiction of

Incorporation)

 

001-15975

(Commission File Number)

 

86-0837251

(IRS Employer

Identification No.)

 

 

BelgiumZuiderlaan 1-3 bus 8, 9000 Ghent, Belgium

 (Address of Principal Executive Offices)

 

 

N/A

(Zip Code)

 

 

011-329-321-7080

(Registrant's telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Section 5—Corporate Governance and Management.

 

Item 5.02 . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 17, 2012, Mr. Stephen Ross, the Company’s Chief Financial Officer and Director, tendered his resignation as an officer and director of the Company, effective on July 17, 2012.

  

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  REMEDENT, INC. ,  
  a Nevada corporation  
       
Dated:   July 17, 2012 By: /s/ Stephen Ross  
   

Stephen Ross

Chief Financial Officer

 

 

 

 

1 Year Elysee Development (PK) Chart

1 Year Elysee Development (PK) Chart

1 Month Elysee Development (PK) Chart

1 Month Elysee Development (PK) Chart

Your Recent History

Delayed Upgrade Clock